Bedside Snapshot
  • Core dose: Hyperkalemia with ECG changes: 1 g (10 mL of 10%) IV over 2–5 min, may repeat; CCB toxicity: 1 g over 5–10 min, repeat every 10–20 min to effect (often 2–4 g total)
  • Onset/duration: Onset within minutes for membrane stabilization; duration 30–60 min (hyperkalemia); does not lower K⁺—only stabilizes membrane
  • Key danger: Severe tissue necrosis with extravasation (potent vesicant)—prefer central line; bradycardia/arrhythmia if given too rapidly; precipitates with bicarbonate (flush line between)
  • Special: 10% solution provides ~27 mg/mL elemental Ca²⁺ (~1.36 mEq/mL); membrane stabilizer in hyperkalemia; antidote for CCB toxicity and hypermagnesemia; contains 3× more elemental calcium than calcium gluconate
Brand & Generic Names
  • Generic Name: calcium chloride (10% solution for injection)
  • Brand Names: CaCl₂ 10% injection (various manufacturers; no single proprietary IV brand is dominant)
Medication Class

Electrolyte; membrane stabilizer; antidote (hyperkalemia, hypermagnesemia, calcium channel blocker toxicity)

Pharmacology

Mechanism of Action:

  • Supplies ionized calcium to restore transmembrane gradients and stabilize cardiac myocyte membranes
  • Antagonizes the membrane effects of hyperkalemia and hypermagnesemia (does not lower K⁺ or Mg²⁺ concentrations)
  • In calcium channel blocker toxicity, increases extracellular Ca²⁺ to overcome competitive blockade at L-type channels and improve contractility/AV conduction

Key Pharmacokinetics / Product Facts:

  • Concentration: 10% calcium chloride contains about 27 mg/mL elemental calcium (~1.36 mEq/mL). A 10 mL dose ≈ 272 mg elemental Ca²⁺ (≈13.6 mEq)
  • Onset IV: minutes for ECG/membrane stabilization
  • Duration: Clinical effect in hyperkalemia typically lasts 30–60 minutes
  • Distribution: Primarily in the extracellular fluid; not dialyzable as an antidote effect
  • Vesicant: Significant risk of tissue necrosis with extravasation—prefer central line when feasible
Indications
  • Membrane stabilization in life-threatening hyperkalemia with ECG changes (peaked T waves, widened QRS, sine-wave)
  • Hypermagnesemia with hypotension, heart block, or respiratory depression
  • Calcium channel blocker (CCB) overdose (e.g., verapamil/diltiazem/amlodipine) as part of multimodal therapy
  • Symptomatic hypocalcemia (e.g., post-massive transfusion citrate toxicity, acute hypocalcemia with tetany/seizures)
  • Hydrofluoric acid exposure (systemic toxicity) as adjunct when severe—local therapy typically uses calcium gluconate
  • Note: Not recommended for routine cardiac arrest use; reserve for the above specific indications
Conditions Treated
  • Life-threatening hyperkalemia with ECG changes
  • Hypermagnesemia (symptomatic)
  • Calcium channel blocker overdose/toxicity
  • Symptomatic hypocalcemia
  • Massive transfusion citrate toxicity
  • Hydrofluoric acid systemic toxicity
Dosing & Administration

Available Forms:

  • 10% solution (100 mg/mL calcium chloride ≈ 27 mg/mL elemental Ca²⁺; ~1.36 mEq/mL)

Adult Dosing:

Indication Dose Notes
Hyperkalemia with ECG changes 1 g (10 mL of 10%) IV over 2–5 min Reassess ECG after 5–10 min; may repeat if changes persist. Duration ~30–60 min
Hypermagnesemia (symptomatic) 1 g IV over 5–10 min Repeat as needed to reverse cardiorespiratory effects
CCB toxicity 1 g IV over 5–10 min; repeat every 10–20 min to effect Often 2–4 g total. Consider continuous infusion (0.2–0.5 mL/kg/h of 10%) with ionized calcium monitoring
Symptomatic hypocalcemia 500 mg–1 g IV over 5–10 min May follow with infusion titrated to ionized calcium

Pediatric Dosing:

  • 20 mg/kg of 10% calcium chloride (0.2 mL/kg; max 1 g) slow IV/IO for hypocalcemia or membrane stabilization
  • For hyperkalemia with ECG changes, similar dosing may be used with close monitoring

Administration:

  • Give via central line when possible
  • If peripheral, ensure large-bore, well-running IV and slow rate with frequent site checks
  • Use separate line from bicarbonate/phosphate to prevent precipitation
Contraindications

Contraindications:

  • Hypercalcemia
  • Relative: Digoxin (digitalis) toxicity—IV calcium can precipitate dysrhythmias; avoid unless life-threatening hyperkalemia with ECG instability, and if used, give cautiously with expert input

Precautions:

  • Avoid mixing or co-infusing with sodium bicarbonate or phosphate solutions—precipitation risk (line incompatibility). Flush lines well between drugs
  • Extravasation risk: tissue necrosis and calcinosis cutis—monitor site closely; stop infusion immediately if pain/swelling/whitening occurs
  • Neonates: avoid concomitant ceftriaxone with IV calcium due to risk of precipitation; follow age-specific guidance
Extravasation Risk: Significant risk of tissue necrosis with extravasation. Prefer central line when feasible.
Adverse Effects

Cardiovascular:

  • Bradycardia
  • Hypotension (especially with rapid bolus)
  • Arrhythmias
  • Syncope

Local Reactions:

  • Burning
  • Pain
  • Phlebitis
  • Severe tissue injury with extravasation

Other:

  • Nausea, vomiting
  • Metallic or chalky taste
  • Flushing
  • Peripheral vasodilation
  • Hypercalcemia with excessive or repeated dosing—monitor ionized calcium
Clinical Pearls
CaCl₂ vs Gluconate: Calcium chloride provides about 3 times more elemental calcium per mL than calcium gluconate and has more predictable IV bioavailability; choose CaCl₂ when rapid effect is critical and central access is available.
Peripheral Access: If only peripheral access is available, calcium gluconate is generally preferred due to lower extravasation risk; if CaCl₂ must be used peripherally, run slowly and monitor the site continuously.
Hyperkalemia Endpoint: ECG is the endpoint in hyperkalemia—not the serum potassium. Repeat bolus if QRS remains wide or T waves remain markedly peaked.
CCB Overdose Management: In CCB overdose, combine with high-dose insulin euglycemia therapy, vasopressors (e.g., norepinephrine), and consider lipid emulsion for select lipophilic agents; calcium alone is often insufficient.
Post-Massive Transfusion: Anticipate citrate-induced hypocalcemia; target ionized calcium in the normal range (e.g., ≥1.0–1.2 mmol/L) while avoiding overshoot.
Compatibility: Do not co-administer with bicarbonate or phosphate; separate lines or flush thoroughly. Avoid Y-site with ceftriaxone in neonates.
Extravasation Management: Stop infusion, leave catheter, aspirate any residual drug, elevate limb; consider hyaluronidase per institutional protocol and apply cold or warm compress per extravasation policy.
References
  • 1. Papadopoulos, J. (2008). Pocket guide to critical care pharmacotherapy. Humana Press.
  • 2. Medscape. (n.d.). Calcium chloride (intravenous) – drug monograph & dosing. Retrieved 2025-11-12, from https://reference.medscape.com
  • 3. Medscape. (n.d.). Hyperkalemia: Treatment & management. Retrieved 2025-11-12, from https://emedicine.medscape.com/article/240903-treatment
  • 4. Medscape. (n.d.). Calcium channel blocker toxicity: Treatment. Retrieved 2025-11-12, from https://emedicine.medscape.com/article/2184611-treatment
  • 5. DrugBank Online. (n.d.). Calcium chloride. Retrieved 2025-11-12, from https://go.drugbank.com
Back to Medication Index
Medical Disclaimer
  • For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
  • Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
  • Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing and formatting this information. All content is reviewed for accuracy.